非唑奈坦(Fezolinetant) - 药物靶点：NK3_在研适应症：潮热，血管舒缩症，更年期综合症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

fezolinant、Fezolinetant (USAN)、A2693

+ [7]

靶点

NK3

作用方式

拮抗剂

作用机制

NK3拮抗剂(神经激肽-3-受体拮抗剂)

治疗领域

心血管疾病其他疾病

在研适应症

潮热血管舒缩症更年期综合症

非在研适应症

肝损伤

原研机构

Ogeda SAEuroscreen Srl

在研机构

Astellas Pharma US, Inc.Astellas Pharma Global Development, Inc.Astellas Pharma Europe BV

+ [2]

非在研机构

安斯泰来制药（中国）有限公司Astellas Pharma Tech Co., Ltd.

Ogeda SA

+ [1]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2023-05-12),

血管舒缩症

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H15FN6OS

InChIKeyPPSNFPASKFYPMN-SECBINFHSA-N

CAS号1629229-37-3

关联

29

项与非唑奈坦相关的临床试验

NCT06957691

/ Not yet recruiting临床2期IIT

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial)

The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy.
The main questions it aims to answer are:
* Does fezolinetant improve the frequency and severity of hot flashes?
* Does fezolinetant cause any harm to the liver?
* Does fezolinetant improve quality of life, sleep quality, fatigue, mood, sexual function, and metabolic parameters?
Researchers will compare how people respond to fezolinetant versus a placebo, which does not contain any active medicine.
Participants will:
* Take fezolinetant or a placebo every day for 4 weeks
* Visit the clinic once every 2 weeks for checkups and tests
* Keep a diary of the number of times and intensity that they experience hot flashes

开始日期2025-12-20

申办/合作机构

The Brigham & Women's Hospital, Inc.

[+1]

NCT06917313

/ Recruiting临床2期IIT

A Randomized Phase II Study to Evaluate the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

This is a phase II, randomized, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs. placebo in reducing moderate to severe vasomotor symptoms (VMS) in breast cancer survivors on endocrine therapy (tamoxifen, aromatase inhibitors). The trial will proceed in a single stage and the total of 92 patients will be randomized in 1:1 fashion to fezolinetant or placebo arm respectively.

开始日期2025-11-01

申办/合作机构

Yale University

[+1]

NCT07077395

/ Not yet recruiting临床2期IIT

Finding Links Between Hot flASHes and CardioVascular Disease

The goal of this clinical trial is to learn if drug fezolinetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer are:
Does drug fezolinetant improve blood vessel health?

开始日期2025-10-01

申办/合作机构

The Massachusetts General Hospital

100 项与非唑奈坦相关的临床结果

登录后查看更多信息

100 项与非唑奈坦相关的转化医学

登录后查看更多信息

100 项与非唑奈坦相关的专利（医药）

登录后查看更多信息

116

项与非唑奈坦相关的文献（医药）

2025-12-01·GYNECOLOGICAL ENDOCRINOLOGY

Targeting vasomotor symptoms with the new drug fezolinetant - an expert overview.

Review

作者: Di Carlo, Costantino ; Villa, Paola ; Cagnacci, Angelo ; Nappi, Rossella E ; Genazzani, Alessandro D ; Simoncini, Tommaso

Menopause is an inevitable event in the life of women who live long enough to reach this milestone. The experience of menopause varies amongst individuals. Menopause has a negative impact on women's life and is associated with symptoms including vasomotor symptoms (VMS), such as hot flushes and night sweats, sleep disturbances and low mood. VMS are bothersome and may have a long duration. Menopause hormone therapy (MHT) is recommended in women with symptoms; however, its use is limited. The recent approval of fezolinetant offers a new therapeutic option for women who suffer from VMS and are unsuitable or averse to MHT. Fezolinetant is a precision drug as it targets the pathological mechanism of VMS showing some effect also on sleep disturbances. Given how variable the experience of menopause is, it is important to offer individualized treatment options to women who suffer from menopause-related symptoms and let them be part of the shared decision making.

2025-10-03·Expert Review of Clinical Pharmacology

Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies

Review

作者: Fuhrman, Jessica ; Yun, Jina ; Indorf, Amy

INTRODUCTION:

Vasomotor symptoms (VMS) and decreased libido are common menopausal symptoms. Patients with breast cancer receiving endocrine therapy experience new or worsening menopausal symptoms. Pharmacologic therapy for VMS has been centered on selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors, gabapentin, and clonidine. These therapeutic options fall short in obtaining adequate symptom relief, illustrating a therapeutic gap in efficacious treatment modalities. There are no historical systemic treatment options for low libido.

AREAS COVERED:

This review summarizes the current pharmacologic therapy for VMS, focusing on the practical considerations for use of the novel VMS (fezolinetant, elinzanetant) and libido agents (flibanserin, bremelanotide). Literature search was completed with PUBMED, Cochrane Library, and Web of Science. Fezolinetant is a novel neurokinin 3 receptor antagonist that has demonstrated clinical benefit in patients without a history of breast cancer. For libido management, flibanserin and bremelanotide act as serotonin/dopaminergic modulators and melanocortin receptor agonists, respectively.

EXPERT OPINION:

These novel agents are eagerly awaited therapeutic options; however, clinical trials excluded breast cancer patients. This review provides clinicians with relevant considerations to assess when recommending these therapies for patients with breast cancer, while awaiting ongoing research to give additional insights for best tailoring therapy for this patient population.

2025-10-01·OBSTETRICS AND GYNECOLOGY

Novel Pharmacotherapies for Menopausal Symptoms

Review

作者: Pal, Lubna ; Liao, Caiyun

Menopausal hormone therapy (HT) is highly effective against vasomotor symptoms (VMS). When HT is contraindicated, ineffective, or unacceptable, alternatives have included antidepressants, antiseizure, and antihypertensive formulations. Novel pharmacologic treatments for VMS have emerged in recent decades, some of which are already approved by the U.S. Food and Drug Administration (FDA) (eg, fezolinetant, a neurokinin 3B antagonist), and others are poised to seek FDA approval (eg, elinzanetant, a dual neurokinin 1B and 3B antagonist, and estetrol, a natural estradiol derivative that is unique to the pregnant state). Oxybutynin was shown to be effective for VMS and could provide additional benefits against overactive bladder, but long-term safety data are needed before wider utilization can be recommended.

228

项与非唑奈坦相关的新闻（医药）

2025-11-26

·ioncology

最新！ABC8专家共识意见：脑转移和绝经后患者症状的管理

编者按：第8届晚期乳腺癌国际共识会议（ABC8）于当地时间2025年11月6～8日在葡萄牙里斯本举行。ABC共识指南是晚期乳腺癌领域首屈一指的国际性权威指南，汇聚了全球晚期乳腺癌领域的“意见领袖”级别专家，基于最新的循证医学证据对前沿和热议话题进行投票以达成共识，为全球晚期乳腺癌临床实践的革新和规范提供指导意见。肿瘤瞭望对乳腺癌脑转移和绝经后症状的管理相关问题的专家意见和投票结果整理如下。 01 脑部影像学不应对无症状患者常规进行脑部影像学检查。该方法适用于所有ABC患者，包括HER2阳性和/或三阴性晚期乳腺癌患者。尽管数据有限，但对于某些无症状的HER2阳性或三阴性晚期乳腺癌患者亚组，可考虑进行脑部影像学检查，例如当发现脑转移会改变治疗方案时，或者当存在极高的肿瘤负荷从而增加发生脑转移的风险时，同时需谨慎权衡过度治疗的风险和时间节点。 02 绝经后症状的管理 Elinzanetant（一种双重NK1和NK3拮抗剂）在针对接受内分泌治疗且每周经历＞35次中/重度潮热的早期乳腺癌女性的随机对照期试验中，表现出高效且良好的耐受性。 Fezolinetant（一种NK3拮抗剂）也可用于潮热管理，但尚未在乳腺癌患者中评估。在获批的情况下，如果与正在进行的抗癌治疗不存在药物相互作用，Elinzanetant也可作为晚期乳腺癌（ABC）患者的选择。（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2025-11-19

·Firstwordpharma

Bayer's Lynkuet approved in EU for menopausal hot flashes

Less than a month after securing approval in the US, Bayer's dual neurokinin-1 and neurokinin-3 (NK-1,3) receptor antagonist Lynkuet (elinzanetant) gained clearance in the EU for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause or caused by adjuvant endocrine therapy related to breast cancer. European approval — which was announced Wednesday — was based on positive results from the Phase III OASIS programme, which comprised OASIS-1, -2, -3 and -4. All of the studies achieved their primary endpoints and key secondary goals, with Lynkuet significantly reducing the frequency and severity of moderate-to-severe VMS, whilst also demonstrating a favourable safety profile. Nick Panay, principal investigator for the OASIS-3 trial, noted that the approval of Lynkuet represents "an important milestone in the area of menopause care," expanding existing options "with a novel targeted hormone-free treatment…to achieve more personalised treatment." Along with the US and EU, Lynkuet has also been approved this year in Australia, Canada, Switzerland and the UK. While Astellas' NK-3 receptor antagonist Veoza/Veozah (fezolinetant) became the first non-hormonal treatment approved for VMS, its launch has underwhelmed and sales have been hampered by a liver safety signal. Doctors seem more receptive to Bayer's drug — according to results from a recent FirstWord poll — with nearly two-thirds of physicians indicating that they would choose Lynkuet over Astellas' therapy for their patients with moderate-to-severe VMS. However, while both non-hormonal treatments require liver monitoring tests, surveyed doctors also expressed concern about the central nervous system (CNS) effects seen with Lynkuet in its clinical trials. Coupled with a recent move by the FDA to remove boxed warnings on hormone therapy related to cardiovascular diseases, breast cancer and probable dementia, the outlook for Lynkuet is far from certain.For further analysis, see Spotlight On: As menopause market gets hormonal again, non-hormonal niche could narrow, and keep an eye out for results from a current poll on how US prescribers are expected to react to the FDA's decision.

临床结果上市批准临床3期

2025-11-11

·安斯泰来中国

安斯泰来发布VEOZAH™（fezolinetant）OPTION-VMS IV期初步真实世界观察性研究数据

安斯泰来发布 VEOZAH™（fezolinetant） OPTION-VMS IV期初步真实世界观察性研究数据 1 越来越广泛的证据持续证实，fezolinetant是更年期相关中重度血管舒缩症状（VMS）的有效治疗方案 2 OPTION-VMS观察性研究的初步分析证实，fezolinetant能改善主观和客观睡眠结局，且该改善具有统计学意义 3 针对工作效率相关结局的进一步分析表明，fezolinetant显著改善活动能力受限情况、整体工作效率下降及“带病上班”现象，且该改善具有统计学意义 2025年10月22日，东京——安斯泰来制药集团（TSE：4503，总裁兼首席执行官：冈村直树）公布了OPTION-VMS IV期纵向观察性研究的初步真实世界数据，首次揭示fezolinetant在真实世界中的应用情况。数据显示，fezolinetant显著减轻更年期相关血管舒缩症状（VMS）困扰，改善主观与客观睡眠结局，并显著缓解包括整体工作效率在内的活动受限情况。血管舒缩症状（VMS），也被称之为潮热和/或盗汗，是更年期常见症状。1,2上述初步结果以“最新突破”壁报形式，于10月21–25日在美国佛罗里达州奥兰多召开的“2025 北美更年期学会年会”上展示。该研究初步分析涵盖了900余位40-75岁的女性，她们均确诊患有更年期VMS，并接受非激素疗法以控制其令人困扰的症状。研究在第12周达到主要终点，同时本次初步数据分析所选取的其他终点（第4、8和12周）也均成功达到。结果显示，接受fezolinetant治疗的女性表现出：在第12周（主要终点）以及第4、8周（次要终点），更年期特异性生活质量量表（MENQOL）血管舒缩症状领域的评分下降，提示更年期相关VMS困扰程度显著改善。在第4、8、12周，患者的总体T评分（更年期症状对整体生活质量影响量表）以及MENQOL其他评分（包括患者报告的性、心理和生理方面）均显著改善（次要终点）。在第4、8、12周，PROMIS SD SF 8b总T评分（患者报告结局测量信息系统睡眠障碍简表8项）显著下降，提示睡眠质量得到改善（次要终点）。活动记录仪监测客观睡眠结局指标显著改善：第4、8、12周睡眠起始后觉醒时间（WASO）显著减少，第4周和第12周的睡眠效率显著提高（次要终点）。在本研究中，与fezolinetant相关的治疗期间出现的不良事件（AEs）发生率低，且与临床研究及上市后数据一致。研究未发现新的安全性信号。初步安全性结果于更年期学会（The Menopause Society）年会上公布，最终分析完成后将提供完整结果。通过PROMIS睡眠障碍简表8项（PROMIS SD SF 8b）、MENQOL量表总评分及各维度评分评估发现，SSRI/SNRI类药物组与其他非激素治疗组（加巴喷丁、奥昔布宁）这两组患者，其报告的睡眠质量也均显示出具有统计学意义的改善。SSRI/SNRI类药物组在睡眠起始后觉醒时间（WASO）和睡眠效率方面，未观察到具有统计学意义的改善；而其他非激素治疗组在所有时间点的睡眠起始后觉醒时间（WASO）上，均呈现出具有统计学意义的改善。此外，针对工作效率相关结局的初步分析显示，在真实临床环境下，使用fezolinetant治疗更年期相关VMS可显著改善WPAI-VMS量表中的各子项，包括真实世界的活动受限、总体工作效率降低以及“带病上班”现象。在SSRIs/SNRIs组和其他非激素疗法组中也观察到同样具有统计学意义的显著改善。北卡大学医学院妇产科系主任、医学博士Genevieve Neal-Perry “这些初步结果证实，fezolinetant是治疗更年期相关、严重影响生活的血管舒缩症状（VMS）的有效方案。除第4周起VMS症状困扰显著减轻之外，女性患者还报告了睡眠、工作效率和日常功能的改善。预计到2030年，全球将有约12亿女性进入围绝经期或绝经期，其中数百万人将承受影响身心健康与职业生活的症状困扰，因此缓解更年期负担刻不容缓。” 更年期症状会给中年女性造成沉重的经济负担，约三分之一的职场女性因此难以胜任工作。已有报告显示，出现严重更年期症状的女性在工作中常感到疲乏，由此导致部分人考虑转行、减少工作时间，甚至退出职场，而这一情况不仅会对个人发展产生重大影响，也会对整体经济情况带来冲击3。安斯泰来美国医学事务部女性健康- fezolinetant负责人，FACOG，骨科医学博士，Shayna Mancuso “这些新的初步研究结果进一步彰显了安斯泰来的承诺——除了关键性临床研究之外，持续深化对fezolinetant的理解，为饱受VMS困扰的人群带来切实的改善。潮热与盗汗是最常见、干扰性最强的更年期相关的VMS症状，若不加以治疗，可能会显著影响睡眠、专注力及日常功能。我们对OPTION-VMS的初步研究结果感到振奋，并期待最终分析结果出炉。” VEOZAH™目前已在全球45个国家获批，包括澳大利亚、加拿大、欧盟、墨西哥、新加坡、瑞士和美国等。关于OPTION-VMS研究 OPTION-VMS研究（NCT06049797）是一项正在进行中的IV期、纵向、观察性研究，纳入40–75 岁、确诊更年期血管舒缩症状（VMS）的女性。入组的患者在真实世界中，接受由医生开具的非激素疗法（non-HT）治疗VMS导致的困扰。研究的主要目标是评估女性患者所经历的VMS困扰的变化；其他的治疗结局包括睡眠质量、更年期相关生活质量、性健康、情绪、工作效率以及安全性。研究在美国50个研究中心共入组998名女性。关于VEOZAH™ （fezolinetant） VEOZAH™（fezolinetant）是一种非激素神经激肽3（NK3）受体拮抗剂，在美国获批用于治疗更年期相关中重度血管舒缩症状（潮热、盗汗）。其机制为阻断KNDy神经元上的NKB结合，调节下丘脑体温中枢神经元活动，从而减少潮热/盗汗的发生频率与严重程度。4,5,6 关于安斯泰来安斯泰来是一家全球生命科学公司，致力于将创新科学转化为患者的价值。我们在肿瘤、眼科、泌尿、免疫和女性健康等疾病领域提供变革性的治疗方案。通过我们研究与开发项目，我们正在为具有高度未满足医疗需求的疾病开创全新的医疗解决方案。了解更多信息，请访问：www.astellas.com 安斯泰来警戒声明本新闻稿中，有关当前计划、估计、战略和信念以及其他非历史事实的陈述，均为关于安斯泰来未来表现的前瞻性陈述。这些陈述是根据管理层结合当前可获得的信息而形成的当前假设和信念得出的，并涉及已知和未知的风险与不确定性。许多因素可能导致实际结果与前瞻性陈述中讨论的结果产生重大差异。这些因素包括但不限于：（i）与制药市场有关的一般经济条件和法律法规的变化，（ii）货币汇率波动，（iii）新产品上市的延迟，（iv）安斯泰来无法有效地销售现有产品和新产品，（v）安斯泰来无法继续有效地研究和开发在竞争激烈的市场中被客户接受的产品，以及（vi）第三方侵犯安斯泰来的知识产权。本新闻稿中包含的有关药品（包括当前正在开发的产品）的信息并不构成广告或医疗建议。 +++ 1.本文翻译自安斯泰来全球新闻稿，原文链接为： https://newsroom.astellas.com/2025-10-22-Astellas-Presents-Preliminary-Real-World-VEOZAHTM-fezolinetant-Data-From-OPTION-VMS-Phase-IV-Observational-Study 2.本文旨在传递医药前沿信息，不构成对任何药物或诊疗方案的推荐或推广。 3.如您想了解更多疾病知识或药品、诊疗相关信息，请咨询医疗卫生专业人士。参考文献 Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005; 3:47. Jones RE, Lopez KH, eds. Human Reproductive Biology. 4th ed. Waltham, MA: Elsevier, 2014:120. Whiteley, J., DiBonaventura, M. dC., Wagner, J-S., Alvir, J., & Shah, S. (2013). The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. Journal of Women’s Health, 22(11), 983-990. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820128 Hill K. The demography of menopause. Maturitas. 1996 Mar;23(2):113-27. doi: 10.1016/0378-5122(95)00968-x. PMID: 8735350. Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104:5893-5905. Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020; 27:382-392.

临床结果

100 项与非唑奈坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11976	非唑奈坦	-	DB15669

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
潮热	英国	Astellas Pharma, Inc.	2023-12-18
血管舒缩症	美国	Astellas Pharma US, Inc.	2023-05-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
更年期综合症	临床3期	美国	Astellas Pharma Global Development, Inc.	2019-07-10
更年期综合症	临床3期	加拿大	Astellas Pharma Global Development, Inc.	2019-07-10
更年期综合症	临床3期	捷克	Astellas Pharma Global Development, Inc.	2019-07-10
更年期综合症	临床3期	拉脱维亚	Astellas Pharma Global Development, Inc.	2019-07-10
更年期综合症	临床3期	波兰	Astellas Pharma Global Development, Inc.	2019-07-10
更年期综合症	临床3期	西班牙	Astellas Pharma Global Development, Inc.	2019-07-10
更年期综合症	临床3期	乌克兰	Astellas Pharma Global Development, Inc.	2019-07-10
更年期综合症	临床3期	英国	Astellas Pharma Global Development, Inc.	2019-07-10
肝损伤	临床1期	美国	Astellas Pharma Global Development, Inc.	2020-09-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04003142 \| NCT04003155 (SKYLIGHT 1 and 2, Pubmed \| Curr Med Res Opin)	临床3期	绝经期综合征 \| 血管舒缩症	-	Fezolinetant 30 mg	膚淵憲艱餘網艱鑰蓋鑰(艱窪鬱網餘網鏇鹽衊築) = 39.4% of participants receiving fezolinetant 45 mg vs. 41.3% receiving placebo 簾願糧遞遞繭齋窪艱餘 (觸繭願衊襯範餘齋糧衊 )	积极	2025-02-01
				Fezolinetant 45 mg
NCT04003142 \| NCT04003389 \| NCT04003155 (SKYLIGHT 1, 2, and 4, Pubmed \| Adv Ther)	临床3期	血管舒缩症	-	Fezolinetant 30 mg	餘築製夢齋簾糧築積選(壓鑰鏇範艱廠鹹鑰憲選) = 2.9-3.2% 餘鏇網鑰衊衊選繭簾廠 (廠淵壓範蓋壓範鬱顧艱 ) 更多	积极	2024-12-30
				Fezolinetant 45 mg
NCT04451226 (MOONLIGHT 3, Pubmed)	临床3期	血管舒缩症	150	Fezolinetant 30 mg	壓網壓夢積夢糧蓋鹹襯(襯鹹繭網糧築憲壓觸鹹) = 繭繭憲網積築糧壓鏇遞遞網衊膚蓋願範願鏇網 (顧製築獵觸鬱艱醖選淵 ) 更多	积极	2024-05-01
Skylight 1，Skylight 2 (Pubmed)	-	潮热	1,022	非唑奈坦	壓膚餘襯餘蓋壓憲願鹽(夢簾願齋顧獵鬱餘鹽鏇) = 觸遞鬱獵製衊夢艱築艱膚製餘齋簾遞範廠淵窪 (醖鏇夢製獵觸廠廠壓餘 ) 更多	积极	2024-05-01
				安慰剂	-
NCT04234204 (Moonlight 1, Pubmed)	-	潮热	301	非唑奈坦	鑰蓋窪夢鹹顧簾築選醖(廠簾簾齋壓鏇餘艱夢鏇): difference = -0.65 (95% CI) 更多	不佳	2024-05-01
				安慰剂
NCT05033886 (DAYLIGHT, Corporate Publications) 人工标引	临床3期	血管舒缩症	453	Fezolinetant	獵艱選鬱觸繭膚壓窪顧(範選襯鬱獵壓齋餘鹹蓋) = fezolinetant 45 mg demonstrated a statistically significant reduction of -1.93 (p<0.001) compared to placebo 鑰壓廠選網衊願艱夢艱 (鬱鹽願製獵艱鹹膚艱獵 ) 达到更多	积极	2023-11-30
				Placebo
NCT05419908 (CTgov)	临床2期	潮热	87	Placebo (Placebo)	鬱襯餘壓鑰鑰蓋鹽選觸(餘構艱壓糧積鬱衊廠簾) = 襯繭窪餘獵膚齋鹹願鏇鏇鬱構窪積鹽衊淵範鏇 (鹹襯淵繭範夢鹽簾憲鹽, 鹽廠鑰遞夢齋築願繭艱 ~ 膚醖構顧壓憲遞顧繭廠) 更多	-	2023-07-25
				Fezolinetant (Fezolinetant)	鬱襯餘壓鑰鑰蓋鹽選觸(餘構艱壓糧積鬱衊廠簾) = 憲齋齋襯糧範積壓壓獵鏇鬱構窪積鹽衊淵範鏇 (鹹襯淵繭範夢鹽簾憲鹽, 衊糧糧窪醖襯糧鏇齋齋 ~ 憲鑰鬱製鹽鹹網鑰鹹構) 更多
NCT04003142 \| NCT04003155 (FDA) 人工标引	临床3期	血管舒缩症	1,022	VEOZAH 45 mg (Trial 1)	簾遞鏇憲範鑰顧醖壓繭(網壓憲繭繭齋廠衊網範) = 遞蓋壓願夢繭繭齋壓顧範鬱簾遞衊艱積構鏇築 (膚鏇網鹹獵網網獵鹹鹽, 0.05) 更多	积极	2023-05-12
				Placebo (Trial 1)	簾遞鏇憲範鑰顧醖壓繭(網壓憲繭繭齋廠衊網範) = 夢鏇鬱構觸鬱願衊艱壓範鬱簾遞衊艱積構鏇築 (膚鏇網鹹獵網網獵鹹鹽, 0.05) 更多
NCT04003389 (SKYLIGHT 4, Pubmed)	临床3期	血管舒缩症	1,831	Fezolinetant 30 mg	鹹淵鑰壓繭膚積壓遞餘(鏇鹽選選齋鏇蓋鹽衊網) = 艱築獵糧淵獵顧築淵衊壓壓遞觸鏇餘鑰構製鏇 (窪窪齋繭齋築選廠淵範 )	-	2023-04-01
				Fezolinetant 45 mg	鏇餘簾範壓遞築鹽網廠(觸獵襯餘鏇構鑰獵壓遞) = 淵構蓋範簾簾餘選襯鬱鏇憲憲網顧積夢鹹鬱構 (鹹艱艱膚築繭顧範淵製, 0 ~ 2.3)
NCT04003389 (SKYLIGHT 4, CTgov)	临床3期	更年期综合症 \| 潮热 \| 血管舒缩症	1,831	placebo (Placebo)	觸選膚鑰窪鑰壓簾築鹹 = 壓淵築鹹齋膚構鑰醖鏇鬱膚醖願壓廠糧艱窪製 (窪餘壓網餘廠鑰鬱觸蓋, 憲鹽鹽齋築齋鹹範鹹獵 ~ 築膚鏇齋構鹽糧獵範鬱) 更多	-	2023-02-01
				fezolinetant (Fezolinetant 30 mg)	觸選膚鑰窪鑰壓簾築鹹 = 廠糧齋膚衊鑰鹽衊鬱餘鬱膚醖願壓廠糧艱窪製 (窪餘壓網餘廠鑰鬱觸蓋, 築襯襯鬱廠構齋膚鹹遞 ~ 淵憲膚範壓觸鏇願遞壓) 更多